GSK-3β: A central kinase for neurodegenerative diseases?;GSK-3β: Une kinase au cœur des maladies neurodegeneratives?

Medecine/Sciences

Volumn 26, Issue 5, 2010, Pages 516-521

  Petit Paitel, Agnès ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID PRECURSOR PROTEIN; CARRIER PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MAPT PROTEIN, HUMAN; NERVE PROTEIN; PRESENILIN; PROTEIN KINASE INHIBITOR; SNCAIP PROTEIN, HUMAN; TAU PROTEIN;

ALZHEIMER DISEASE; APOPTOSIS; BIOLOGICAL MODEL; BRAIN; DEGENERATIVE DISEASE; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; LEWY BODY; METABOLISM; MITOCHONDRION; NEUROFIBRILLARY TANGLE; PARKINSON DISEASE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; REVIEW; SENILE PLAQUE;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; APOPTOSIS; BRAIN; CARRIER PROTEINS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LEWY BODIES; MITOCHONDRIA; MODELS, NEUROLOGICAL; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; PARKINSON DISEASE; PHOSPHORYLATION; PRESENILINS; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SENILE PLAQUES; TAU PROTEINS;

EID: 77952960864     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2010265516     Document Type: Review

References (44)

1. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001; 65: 391-426.
2. 2. Leroy K, yilmaz Z, Brion JP. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 2007; 33: 43-55. (Pubitemid 46090309)
3. 3. Brownlees J, Irving NG, Brion JP, et al. Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3beta transgenes. Neuroreport 1997; 8: 3251-3255 (Pubitemid 27461376)
4. 4. Engel T, Hernandez F, Avila J, et al. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 2006; 26: 5083-5090 (Pubitemid 44315289)
5. Aplin AE, Gibb GM, Jacobsen JS, et al. In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. J Neurochem 1996; 67: 699-707.
6. Qing H, He G, Ly PT, et al. Valproic acid inhibits Abeta production, neuntic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 2008; 205: 2781-2789
7. Su y, Ryder J, Li B, et al. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 2004; 43: 6899-6908
8. 8. Terwel D, Muyllaert D, Dewachter I, et al. Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol 2008; 172: 786-798 (Pubitemid 351354550)
9. Checler F, Alves da Costa C, Dumanchin-Njock C, et al. Métabolisme du précurseur du peptide amyloide et présénilines. Med Sci (Paris) 2002 ; 18: 717-724 (Pubitemid 34764453)
10. 10. Takashima A, Murayama M, Murayama O, et al. Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc Natl Acad Sci USA 1998; 95: 9637-9641 (Pubitemid 28506284)
11. Murayama M, Tanaka S, Palacino J, et al. Direct association of presenilin-1 with beta-catenin. FEBS Lett 1998; 433: 73-77
12. 12. Rockenstein E, Torrance M, Adame A, et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 2007; 27: 1981-1991 (Pubitemid 46310321)
13. 13. Nakashima H, Ishihara T, Suguimoto P, et al. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol 2005; 110: 547-556 (Pubitemid 41763984)
14. 14. Engel T, Goni-Oliver P, Lucas JJ, et al. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 2006; 99: 1445-1455 (Pubitemid 44924224)
15. 15. Caccamo A, Oddo S, Tran LX, et al. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 2007; 170: 1669-1675 (Pubitemid 47339311)
16. Hu S, Begum AN, Jones MR, et al. GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 2009 ; 33: 193-206.
17. Jope RS, Bijur GN. Mood stabilizers, glycogen synthase kinase-3beta and cell survival. Mol Psychiatry 2002; 7 (suppl 1) : S35-45.
18. 18. Gomez-Sintes R, Hernandez F, Bortolozzi A, et al. Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J 2007; 26: 2743-2754 (Pubitemid 46884288)
19. 19. Peineau S, Taghibiglou C, Bradley C, et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 2007; 53: 703-717 (Pubitemid 46283369)
20. Bell EC, Willson MC, Wilman AH, et al. Differential effects of chronic lithium and valproate on brain activation in healthy volunteers. Hum Psychopharmacol 2005; 20: 415-424
21. Martinez A, Perez Dl. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?; Alzheimers Dis 2008; 15: 181-191
22. Dagda RK, Zhu J, Chu CT. Mitochondrial kinases in Parkinson's disease: Converging insights from neurotoxin and genetic models. Mitochondrion 2009; 9: 289-298
23. Nagao M, Hayashi H. Glycogen synthase kinase-3beta is associated with Parkinson's disease. Neurosci Lett 2009; 449: 103-107
24. 24. Wang W, yang Y, ying C, et al. Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 2007; 52: 1678-1684 (Pubitemid 46843143)
25. Petit-Paitel A, Brau F, Cazareth J, et al. Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons. PIoS One 2009; 4: e5491.
26. 26. Arima K, Hirai S, Sunohara N, et al. Cellular co-localization of phosphorylated tau- and NACP/ alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res 1999; 843: 53-61. (Pubitemid 29488694)
27. Duda JE, Giasson BI, Mabon ME, et al. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol 2002: 104: 7-11.
28. Duka T, Duka V, Joyce J N, et al. Alpha-synuclein contributes to GSK-3(beta)-catalyzed Tau phosphorylation in Parkinson's disease models. Faseb J 2009 ; 23: 2820-2830
29. 29. Ribeiro CS, Carneiro K, Ross CA, et al. Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein. J Biol Chem 2002; 277: 23927-23933 (Pubitemid 34952237)
30. 30. Coux O, Piechaczyk M. Le système ubiquitine/protéasome : un ensemble (de) complexe(s) pour dégrader les protéines. Med Sci (Paris) 2000 ; 16: 623-629 (Pubitemid 30326188)
31. 31. Avraham E, Szargel R, Eyal A, et al. Glycogen synthase kinase 3beta modulates synphilin-1 ubiquitylation and cellular inclusion formation by SIAH: implications for proteasomal function and Lewy body formation. J Biol Chem 2005: 280: 42877-42886 (Pubitemid 43049250)
32. Park SS, Zhao H, Mueller RA, et al. Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta. J Mol Cell Cardiol 2006; 40: 708-716
33. 33. Youdim MB, Arraf Z. Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 2004 ; 46: 1130-1140 (Pubitemid 38529937)
34. Carmichael J, Sugars KL, Bao YP, et al. Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem 2002; 277: 33791-33798
35. Sarkar S, Ravikumar B, Floto RA, et al. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ 2009; 16: 46-56.
36. yang W, Leystra-Lantz C, Strong MJ. Upregulation of GSK3beta expression in frontal and temporal cortex in ALS with cognitive impairment (ALSci). Brain Res 2008 ; 1196: 131-139
37. Feng HL, Leng Y, Ma CH, et al. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 2008; 155: 567-572
38. 38. Perez M, Rojo Al, Wandosell F, et al. Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3. Biochem J 2003; 372: 129-136 (Pubitemid 36609614)
39. Heiseke A, Aguib Y, Riemer C, et al. Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy. J Neurochem 2009; 109: 25-34.
40. Andreu P, Perret C, Romagnolo B. Wnt et cellules souches intestinales: des liaisons dangereuse Med Sci (Paris) 2006 ; 22: 693-695
41. Clavaguera F, Goedert M, Tolnay M. Induction et propagation de la pathologie par la protéine tau chez un modèle murin de la maladie d'Alzheimer. Med Sci (Paris) 2010; 26: 123-124
42. 42. Corti O, Brice A. La maladie de Parkinson: que nous apprennent les gènes responsables des formes familiales ? Med Sci (Pans) 2003 ; 19: 613-619 (Pubitemid 36569695)
43. Langui D, Lachapelle F, Duyckaerts C. Modèles animaux des maladies neuro-dégénératives. Med Sci (Paris) 2007 ; 23: 180-186
44. Lelan F, Damier P. Les neurones dopaminergiques greffés dans la maladie de Parkinson sont-il à leur tour atteints par le processus dégénératif ? Med Sci (Paris) 2009 ; 25: 15-16